Eikon Therapeutics was co-founded by UC Berkeley researchers, one of whom has already received a Nobel Prize for the underlying technology.

Eikon Therapeutics, a US-based drug discovery and development company co-founded by University of California (UC), Berkeley researchers, has completed a $517.8m series B round from investors including UC Investments.

Insurance provider Harel Insurance took part in the round, as did T Rowe Price Associates, Canada Pension Plan Investment Board, EcoR1 Capital, StepStone Group, Soros Capital, Schroders Capital, General Catalyst, E15 VC and Hartford HealthCare Endowment.

Abu Dhabi Investment Authority’s ADIA subsidiary and AME Cloud Ventures were also among the investors,…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?
Thierry Heles

Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).